Over the past several decades,major strides have been made in the management of heart failure with reduced ejection fraction(HFrEF).The 2022 AHA/ACC/HFSA guidelines recommend four drug classes in all patients with sym...Over the past several decades,major strides have been made in the management of heart failure with reduced ejection fraction(HFrEF).The 2022 AHA/ACC/HFSA guidelines recommend four drug classes in all patients with symptomatic HFrEF[1].This guideline directed therapy(GDMT)includes renin angiotensin receptor(RAAS)blockade,preferentially with angiotensin receptor neprilysin inhibitors(ARNI),beta blockers,mineralocorticoid receptor antagonists(MRA),and sodium-glucose cotransporter inhibitors(SGLT2i).展开更多
文摘Over the past several decades,major strides have been made in the management of heart failure with reduced ejection fraction(HFrEF).The 2022 AHA/ACC/HFSA guidelines recommend four drug classes in all patients with symptomatic HFrEF[1].This guideline directed therapy(GDMT)includes renin angiotensin receptor(RAAS)blockade,preferentially with angiotensin receptor neprilysin inhibitors(ARNI),beta blockers,mineralocorticoid receptor antagonists(MRA),and sodium-glucose cotransporter inhibitors(SGLT2i).
